GlassScriptPhysician profile
Gary J Misko
NPI 1033213236
$2,325.96
in general payments reported to CMS, 2019-2025
23 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $118 · 2021: $24.28 · 2023: $292 · 2024: $950 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,166.83 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $341.78 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $152.10 | 2023 | |
| Novo Nordisk INC | $88.79 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.36 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $74.76 | 2019-2021 | |
| Exact Sciences Corporation | $50.01 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.63 | 2019 | |
| Corcept Therapeutics | $33.86 | 2025 | Korlym |
| Abbvie INC. | $33.73 | 2024 | |
| Vanda Pharmaceuticals INC. | $32.45 | 2025 | Fanapt |
| Saluda Medical Americas, INC. | $29.96 | 2024 | Evoke |
| Amgen INC. | $29.27 | 2023 | Repatha |
| Glaxosmithkline, LLC. | $28.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $24.41 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.87 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $15.72 | 2023 | |
| Esperion Therapeutics, INC. | $15.56 | 2024 | Nexletol |
| Dexcom, INC. | $15.22 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $14.64 | 2020 | |
| Gilead Sciences, INC. | $14.33 | 2019 | |
| Medicure Pharma INC. | $13.92 | 2025 | Zypitamag |
| Dermira, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Misko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.